Racial Disparities in Latin American Patients-FLEX, Mazo Canola et al., SABCS 2023 Abstract
SABCS 2023, PS18-04 Authors: Marcela Mazo Canola et al.
Read MoreMammaPrint UltraLow from FLEX Study, Graham et al., SABCS 2023 Abstract
SABCS 2023, PO1-02-11 Authors: Cathy Graham et al.
Read MoreHER2-low in the FLEX Study, Sivapiragasam et al., SABCS 2023 Abstract
SABCS 2023, PO4-02-02 Authors: Sivapiragasam et al.
Read MoreResponse Predictive Subtypes in Lobular Tumors-FLEX, Mukhtar et al., SABCS 2023 Abstract
SABCS 2023, PO4-02-03 Authors: Mukhtar et al.
Read MoreMINDACT & TAILORx Exploratory Comparison, Neven et al., SABCS 2023 Abstract
SABCS 2023, PO1-02-05 Authors: Patrick Neven et al.
Read MoreFLEX Study Update, Alberty et al, SABCS 2023 Abstract
SABCS 2023, PO3-02-02 Authors: JJ Alberty-Oller, et al.
Read MoreComparison of genomic test scores and CT Indications – SABCS 2023
SABCS 2023 Author: Vidal, Singh et al.
Read MoreNurse Navigators’ Role in Personalized ESBC Treatment, A Case Study
Publication: Journal of Oncology Navigation & Survivorship, Nov 2023, Vol 14 Authors: Jo Weathers, RN, BSN, OCN, ONN-CG; Jane Baker, RN, MSN; Victoria Poillucci, DNP, MEd, ACNP-BC; Christina Z. Page, AOCNP, AGPCNP-BC
Read MoreThe Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
Publication: Annals of Surgical Oncology, Sept 1 2023 Authors: Peter Blumencranz MD, FACS, Mehran Habibi MD, Steve Shivers PhD, Geza Acs MD, Lisa E. Blumencranz PhD, Erin B. Yoder MS, Bastiaan van der Baan MS, Andrea R. Menicucci PhD, Patricia Dauer PhD, William Audeh MD & Charles E. Cox MD
Read MoreTRAIN 2 Trial: BluePrint predicts response to neoadjuvant pertuzumab in HER2-positive
Breast Cancer Research 25, Article Number: 71 (2023) Authors: Liefaard et al.
Read More
